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Abstract 
Background:  Physical impairments and activity restrictions cause significant morbidity after 
surgery for sarcoma. Yet objective assessments of key components of balance, gait and 
physical activity (PA), using valid and reliable outcome measures, is lacking in routine clinical 
practice.  
Purpose of Review: We therefore performed a systematic review to identify studies 
quantifying balance, gait and PA in clinically useful ways, after lower extremity sarcoma. 
Patients and Methods: Relevant articles quantifying balance, gait and PA in patients who 
underwent surgery for lower extremity bone or soft tissue sarcoma were identified from 
Medline, Embase, Scopus, and Web of Science up to February 2016. Results were compiled 
by principal research findings, objective measures used, their ability to detect differences 
between important clinical groups, change over time and reliability. 
Results:  Eighteen articles were included. Surgery had a significant impact on outcomes 
(p<0.05). A wide range of measures and concerns about accuracy of measurement were noted, 
as gait and PA measures did not discriminate between distinct clinical groups such as limb 
sparing surgery and amputation, and did not detect changes over time. Few studies investigated 
reliability (n=1) and sensitivity to change (n=4).   
Conclusion: There is a deficit of studies quantifying balance, gait and PA in patients with 
lower extremity sarcoma. Studies did not use consistent, valid and reliable instruments. There 
is an urgent need to develop novel objective measures of physical functioning in this patient 
group to encourage evidence-based clinical care. 
Key words: balance, gait, physical activity, activity restrictions, functional outcomes, 
musculoskeletal cancer. 
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Introduction 
Sarcomas are a heterogeneous group of rare cancers arising in bone and soft tissues, in almost 
any anatomical location, and with an estimated incidence of 27,908 new cases per year in 
Europe (1) . About 84% are soft tissue sarcomas (STS), the incidence of which increases with 
age, and 14% are bone sarcomas (BS), which occur more frequently in children and adolescents 
(1). Multi-modality treatment for lower extremity sarcomas includes chemotherapy, 
radiotherapy and major surgery (2, 3). Although 85% of patients undergo limb sparing surgery 
(LSS), many face complications such as implant failure, limb shortening, wound healing, and 
infection (4), sometimes demanding multiple revision surgeries. In some cases amputation 
(AMP) is necessary.  
 
Survivors of childhood cancer (also referred to as childhood cancer survivors, CS) face 
significant long term activity restrictions, education and employment problems due to 
extensive surgery (5, 6).  On the other hand, older survivors of adult cancer (also referred to as 
adult cancer survivors, AS) commonly develop impaired balance and gait due to the combined 
effect of pre-existing comorbidities and surgery on the locomotor system (7). Poor balance and 
gait renders patients inactive, thereby further increasing health risks; for example: risk of falls, 
exposing them to serious consequences of fractures, disability and loss of independence (8-10), 
ultimately jeopardising their overall quality of life (QoL) (11, 12). Therefore quantifying 
balance, gait and physical activity (PA) levels in the pre-operative, early post-operative and 
rehabilitation period, can present clinicians with important information about the severity and 
nature of physical limitations. This can help identify “at risk” patients, suitable for targeted 
interventions and early rehabilitation referrals, which is key to enhanced recovery (13). 
Furthermore, as new techniques develop for the surgical treatment of extremity sarcomas, 
better measures of physical functioning are needed for their objective evaluation. 
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Although traditional measures of physical functioning (functional outcomes) in sarcoma 
survivors, the Toronto Extremity Salvage Score (TESS) (14), and the Musculoskeletal Tumour 
Society Scoring system (MSTS) (15) measure disability and impairments like joint range of 
movement, muscle strength, joint stability, pain, deformity, functional activity and emotional 
acceptance, respectively, they do not capture any objective information on balance, gait and 
PA. Moreover, TESS relies on subjective recall and does not relate to objective data about gait 
and PA (16), posing a difficulty in understanding underlying interactions. In spite of increasing 
research into balance, gait and PA in recent years (17-19), common barriers to clinical 
translation are high costs or that devices are cumbersome and inaccurate.  
Cost-effective clinically useful accurate, valid and reliable outcome measures are urgently 
needed to ensure effective clinical management. (20).  Useful measures would accurately detect 
differences between distinct treatment groups (LSS vs AMP), shed light on interactions with 
important clinical factors (for example: joint range, muscle strength), measure the impact of 
treatments (chemotherapy, surgery, rehabilitation strategies) over time and show reliability in 
repeat measurements (21, 22). Therefore, the aim of this paper was to systematically review 
the literature to identify studies quantifying balance, gait and PA in patients treated for lower 
extremity sarcoma, using methods which are likely to be easily translated into routine clinical 
practice. 
Specific objectives are: 
1. To identify methods used to quantify balance, gait or PA in patients after treatment for 
sarcoma, with the potential for translation into busy clinic settings. 
2. To investigate whether these measures have been tested for validity, reliability and 
sensitivity to change. 
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Methods 
Search Strategy:  
We identified relevant studies by searching four electronic databases, Medline, Embase, 
Scopus, and Web of Science up to February 2016. An initial search combined four main search 
terms using the Boolean “AND” operator: 1) Bone neoplasms OR Soft tissue neoplasms 2) 
Physical functioning 3) Extremities 4) Measurement (Appendix A). After reviewing eligible 
articles, additional search terms covering the three physical functioning domains of balance, 
gait and PA were identified, and a second search implementing these terms was undertaken to 
ensure no relevant articles were missed. (Appendix B). 
Selection of studies: 
Search results from each database were imported into EndNote bibliographic management 
software (Thomson Reuters, Endnote version X7). The titles and abstracts of these references 
were screened by two independent reviewers (SF and CG) and appropriate articles selected. 
Differences in opinion were resolved by consensus. Additional hand searching of reference 
lists of included articles and excluded reviews identified further studies for inclusion (Figure 
1).  Studies were selected using the eligibility criteria outlined.  
Inclusion Criteria:  
1. Primary research investigating objective measures of postural balance, gait and 
physical activity in patients treated for lower extremity bone or soft tissue tumours. 
2. Devices which have the potential to be used in routine busy clinical settings (advantages 
such as rapid to measure, portable depending on outcome measured) 
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Exclusion Criteria: 
1. Conference proceedings or non-journal articles such as commentaries whose 
methodology is not clear. 
2. Non-English articles 
3. Including purely upper extremity tumours. 
4. Case report/case reports 
5. Full text not available after considerable search. 
6. Cumbersome laboratory systems such as a Gait laboratory, EMG systems etc. 
7. Review articles (secondary research) 
Data Extraction: 
The data extraction tool was prepared by the 2 independent reviewers, based on clinical 
information, and the psychometric properties of outcome measures. The tool consisted of 2 
main tables. The first table comprised the patient population, demographics, treatments, 
instruments used to capture outcomes, objective measures used and main results/conclusions 
of the study (Table 2). The second table comprised psychometric properties, including validity, 
reliability and sensitivity of change of balance, gait and PA measures in these studies (Table 
3). Data were extracted by the first independent reviewer (SF) using the tool and were 
reviewed, by a second independent reviewer (CG), to ensure accuracy and rigour.  
Quality assessment tool:  
As no standardised quality assessment tool is available for this topic (23), a checklist (Table 4, 
Section 1) was developed, including both methodological and patient criteria. This comprised 
a comprehensive list of criteria from the Critical Appraisals Skills Programme (CASP) (CASP, 
2014) and Strengthening The Reporting of Observational Studies in Epidemiology (STROBE) 
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(24) for methodological issues; criteria related to patient specific issues were selected from a 
checklist developed in a previous study (25),[which was adapted from (26-28)]. The maximum 
score achievable was 18 (100%): studies achieving a score of greater than 70% were defined 
as “high quality”, 50-70% were “moderate quality” and less than 50% were “low quality” (29). 
A quality assessment of selected papers was conducted but was not used as a selection criterion.  
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Results: 
A total of 2661 papers were identified, of which 18 were included (Figure 1, Table 1) published 
between 1998 and 2013. Of the 18 studies, 5 were case series (30-34), 7 cross-sectional studies 
(7, 16, 35-39), 2 prospective studies (40, 41), 2 prospective longitudinal studies (assessment at 
multiple time points) (6, 42), 1 retrospective cohort study (43)  and 1 validity and reliability 
(44). 11 were high quality studies (>70% rating) and 7 moderate quality (50-70% rating) (Table 
4, Section 2).  
Of these 18 studies, 1 was about balance (31), 7 gait (30, 32-34, 36, 38, 39) and 10 PA (6, 7, 
16, 35, 37, 40-44) (Table 2).  The sample size in the studies ranged from 4 to 82. 
15 were conducted in patients with bone tumours (BT) only and 3 in a mixed group of BT 
and STS. In 12 studies, patients had LSS and in 6 LSS+AMP. The age of patients ranged 
from 9 to 85 years and time since surgery from 6 weeks to 39 years. In longitudinal cohorts, 
patients were assessed pre-operatively and at several time points up to a maximum of 24 
months.  7 were childhood Cancer survivors (CS), 5 adult cancer survivors (AS), 4 CS+AS 
and 2 not specified.                                                                                                                                                                                                                                                                            
A. Methods used to quantify balance, gait and PA outcomes (Table 2): 
A wide range of outcome measures were used to quantify balance, gait and PA. These included 
amplitude of the center of pressure (ACP), velocity of the center of pressure (VCP), step 
velocity, walking speed, stride length, step cycle duration, gait symmetry, double support time, 
swing time, stride time, steps/day, time spent walking, gait cycles (gcs)/day, strides/day, and 
movement intensity. 10 instruments were used to capture outcomes included force platforms, 
foot switches such as VA Rancho - Footswitch Stride Analyser ®, gaitmats such as 
GaitMatTMII and GaitRite ®, pedometer and activity monitors such as Dynaport ® ADL, 
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StepWatch™ Activity Monitor, Step Activity Monitor ® (SAM), Uptimer device ® and 
Actilog ® V3.0 
 
Validity, Reliability and Responsiveness to change over time. (Table 3): 
I. Indicators of validity including outcomes in different clinical groups and the impact 
of clinical factors: 
Patients presented with significantly diminished balance, gait and ambulatory (walking) PA 
compared to healthy controls in the short and long term (6, 31, 34), where patients spent most 
of their time sitting (54+/-18% of the time) (7, 16). LSS and AMP are distinct clinical groups, 
and most studies demonstrated no significant differences in ambulatory PA between LSS and 
AMP (35, 43, 44). However, one study showed that patients with above knee AMP, resection 
alone cases (simple LSS) and autoclaved bone reconstructions achieved a higher number of 
steps than patients who underwent complex LSS such as the Kotz modular reconstruction 
system, including total knee replacement (TKR) or semiconstrained total hip replacement 
(THR), (7). BT patients (6001 ± 2684 gcs)) demonstrated lower average daily step counts than 
STS patients (7758 ± 3835 gcs ) (p < 0.05) (7). Patients with complications such as wound-
healing problems, superficial or deep infection demonstrated significantly lower intensity of 
PA at 18 months, than those without complications (6). In terms of correlations with existing 
measures, contrasting results were seen, for example: in one study the number of step cycles 
or percentage of ambulatory time were not correlated with TESS or MSTS (16) but in others, 
MSTS correlated with “time spent walking” (44), and with steps/day (number of steps = 0.001 
X MSTS score ± 14.499) (7). In addition, although instruments assessing similar outcomes (for 
example: Various walking activities (VWA) and Timed Up and Down Stairs (TUDS)), detected 
differences between LSS and AMP, the general physical activity (GPA) from the Actilog 
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activity monitor did not detect differences between these groups (35). Interestingly, age did not 
relate to PA, but body mass index (BMI) was negatively correlated with duration of data 
collection (p<0.01) (16). In addition, although time since surgery, length of bone resected and 
ROM did not correlate with PA, muscle strength was significantly positively correlated with 
PA (Sugiura et al, 2001).  
II. Sensitivity or responsiveness to change: 
Only 4 studies investigated change in outcomes over time. Of these, step-cycle duration, 
walking speed, and gait symmetry recorded by footswitches were sensitive to change over time, 
as at the end of rehabilitation gait improved compared to baseline (p<0.05) (34). Similarly PA 
captured by StepWatch™ Activity Monitor was sensitive to change from 6 weeks to 18 months 
post-surgery (6). However, contrasting results in another study revealed GPA from the Actilog 
monitor was not sensitive to change over time from 3 to 12 months post-surgery, although there 
was a change in PA detected by the Baecke questionnaire. (42).   
III. Reliability:  
Only 1 reliability study was undertaken, with good intraclass correlation coefficient (ICC) 
from 0.65 to 0.91. ICC values for PA volume in walking time were 0.65, standing time were 
0.83, sitting time were 0.75. ICC values for movement intensity (m/s2) was 0.91 in walking, 
0.69 in standing, 0.79 in sitting and a total of 0.91 in walking, standing or sitting (Van Dam et 
al, 2001). 
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Discussion 
We have reviewed the literature and identified 18 relevant articles quantifying balance, gait 
and PA. Studies were highly variable, as they used a wide range of outcome measures, 
investigated different age groups, clinical sub-groups, ranged from case series to longitudinal 
studies, publication year from 1996 to 2013, and 11 were high quality and 7 moderate quality, 
posing a difficulty in synthesizing results.  
Very few studies investigated aspects of validity of outcome measures raising questions on 
accuracy of measures and trustworthiness of results obtained. For example: Only one study 
investigated reliability and four sensitivity to change over time. Furthermore, overall results 
were perhaps surprising that some gait and PA measures were unable to distinguish between 
distinct clinical groups, such as LSS and AMP (35, 43, 44). In contrast, in another study, 
patients who had above knee AMP achieved a higher number of steps than complex LSS 
patients (Kotz TKR and Semiconstrained THR), and complex LSS were significantly different 
from simple LSS groups (resection alone) (7). The inability to distinguish between LSS and 
AMP groups might therefore be due to the wide variation in the level and complexity of surgery 
in each group, as well as the inaccuracy or inapplicability of measures to the clinical scenario. 
It was interesting that GPA from Actilog could not detect differences between LSS and AMP, 
whilst TUDS and VWA did. (35). Although it could be argued that this is because GPA, TUDS, 
VWA measure different attributes of physical functioning it is of note that in another study, 
Baecke questionnaire measuring PA, was sensitive to changes in PA from 3 to 12 months (p < 
0.01), but the GPA was not. (42). Therefore clearly GPA is not sensitive to change of PA over 
time. This could be attributed to non-linear methods of data analysis being more sensitive than 
linear methods, for PA data from activity monitors (45). For example: Pattern of PA 
(Distribution of activity also referred to as alpha (α)) was found to be more sensitive than 
volume (percentage of time spent in an activity) in other clinical groups (46).  
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Although few studies demonstrated that established measures such as TESS/MSTS were 
related to total steps/day (16, 44), these measures alone do not provide a complete clinical 
picture of a patient’s impairment, disability and activity restrictions. This hampers clinicians 
from planning holistic management strategies often triggering poorer outcomes. It is clear that 
balance, gait and PA measures identified in this review provide new objective clinical 
information, completely different from TESS/MSTS, re-emphasizing the need to collect novel 
measures in conjunction with established measures in routine clinical practice. This is useful 
in planning clinical and cost-effective management strategies and significantly improving 
outcomes. However, a significant barrier to clinical use is the lack of validity and reliability 
testing of measures. This could present clinicians with potentially inaccurate information and 
may increase the risk that clinically important information is missed. In addition, costly or 
heavy devices pose added difficulties to clinical translation.  
The ideal device for use in a clinical setting would be valid and reliable (47), cost-effective (7), 
portable and light-weight and able to be used for self-monitoring. Mounting such a device on 
the lower back using a belt (44), seems to be a suitable and pragmatic approach and avoids 
problems with limb mounting, such as the effects of major surgery, scars and amputation. 
Modern accelerometers have been used to improve balance and gait rehabilitation, by providing 
immediate biofeedback (48-50). For example: audio biofeedback from an accelerometer has 
been used to improve balance (51). Similarly simple inexpensive activity monitors have been 
used to monitor and guide PA rehabilitation strategies in home settings. (52, 53).   
The studies identified showed that balance, gait and PA were significantly poorer in patients 
than healthy controls in both the short and long term, (6, 31-33). This clearly has clinical 
implications, emphasizing the importance of rehabilitation in both acute and chronic phases. 
Furthermore, the long-term rehabilitation of patients with complications requires a focus on 
intensity training, as intensity of PA continued to remain affected at 18 months post-surgery 
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(6).  Other approaches which need to become a part of rehabilitation include reducing 
dependency on visual cues during progressive balance training (31).  In addition, clinical 
factors such as proximal muscle strength and BMI significantly correlated with gait and PA 
(p<0.05), but not length of the bone resected or ROM  (36) (7), stressing the importance of 
prioritising proximal muscle strengthening and weight reduction during physiotherapy. 
Rehabilitation of the unaffected extremity is also important as there may be bilateral hip muscle 
weakness (30), possibly because of over-compensation for the affected extremity.   
This is the first systematic review investigating the measurement of balance, gait and PA in 
patients treated for lower extremity sarcoma. The main strengths of the review are a robust 
search strategy and a quality assessment tool specifically developed for this heterogenous 
patient group. Weaknesses of the review include sample size was low in some studies, 
presenting difficulty in generalizability of results. Some papers were older, and patients were 
treated at a time when primary amputation rates were higher, leading to a higher number of 
patients presenting with poorer physical function and is a potential source of bias. Although 
one paper showed contrasting results (47), the real reason could be that this sample is from an 
older study and may be significantly different to that seen in the clinic in the modern era.  Other 
findings which would be important to account for in future studies are that balance and gait 
were significantly affected in unbalanced tasks (31, 34), arguing for the collection of outcomes 
in real life challenging situations. It is also important to account for differences in ambulatory 
PA at weekends, as a study demonstrated that LSS patients walked only 95% of the steps 
achieved during weekdays (16). 
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Conclusion: 
There is a deficit in studies quantifying balance, gait and PA in patients treated for lower 
extremity sarcoma. Of the studies that exist, the majority did not use consistent, valid and 
reliable instruments developed specifically for sarcoma. Novel cost-effective, portable, valid 
and reliable instruments specific to assessing balance, gait and PA are important to develop, to 
gain accurate information, in patients treated for lower extremity sarcoma. Better measures of 
physical functioning are important when considering the impact of treatment and are essential 
if clinical management is to be improved. Wearable, portable and cost-effective tools such as 
activity monitors could be possible solutions, as are easy to apply  and have a good potential 
for clinical translation.   
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Figure Legends: 
 
Figure 1: Selection of Papers for this review. 
Figure 1: Selection of Papers for this review 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 2644 articles papers identified in the 
initial + updated search (additional 
search terms) upto Feb 2016. 
2661 potentially eligible articles before 
review of title and abstract of papers. 
2555 articles rejected after 
review of title and abstract. 
89 remaining before review of full texts. 
18 papers included in the systematic review. 
71 articles rejected after 
review of full text. 
17 potentially eligible papers 
identified by reviewing 
reference lists of related reviews 
and eligible articles. 
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Table 1: Numbers of articles identified by database 
Database References found 
following automated 
de-duplication to 
April 2014 
References found 
following automated 
de-duplication  
May 2014-Dec 2015 
Updated terms 
added Feb 2016 
(articles found by 
previous searches 
have been 
removed) 
Medline (Ovid) 132 17 29 
Embase (Ovid) 285 63 117 
Scopus 1412 293 43 
Web of Science 154 33 66 
TOTAL  1983 406 255 
GRAND TOTAL   2644 
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Table 2: Objective Measures of Balance, Gait and PA. 
No. Author, 
Year and 
Type of 
study 
Num
ber 
of 
patie
nts 
Age (in 
years)  
Childho
od 
cancer 
survivor
s 
(CS)/Ad
ult 
cancer 
survivor
s (AS) 
Type of 
tumour 
Procedu
re [Limb 
Sparing 
Surgery 
(LSS)/ 
Amputat
ion 
(AMP)] 
 
Follow 
Up 
Control 
group 
Device/ 
Instrument 
used 
Parameters 
measured 
Main Results/Conclusion 
  
Impairment – Balance 
Patient group  - LSS 
1.   De 
Visser et 
al, 2001 
– A case 
series.  
N= 
11 
Mean 
age (+/-
SD) 
41.45 
CS+AS 10 patients 
with a 
PMBT in 
the lower 
LSS 
(Resectio
n  with or 
without 
N/A 10 
healthy 
controls.  
Force 
Platform: 
wooden plate 
on four force 
Balance 
measures: 
Measure of  
ACP (in 
millimetre 
After LSS for lower extremity 
sarcoma, patients demonstrated no 
significant differences in balance 
(ACP and VCP) compared to 
healthy controls, in upright standing. 
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+/-
17.42 
years. 
extremity 
(ilium, 
proximal 
and distal 
femur) and 
one with a 
STS in the 
gluteal 
region. 
reconstru
ction) 
transducers 
and recorded  
vertical ground 
reaction 
forces. 
(mm)) and the 
VCP 
(millimetre/sec
ond (mm/sec) 
in normal 
standing and 
standing on 
balance board, 
with eyes 
open, eyes 
closed and a 
task 
demanding 
attention. 
 
However, upright standing in more 
challenging conditions such as 
visual and cognitive loads is 
associated with significantly higher 
ACP and VCP compared to normal 
standing. This suggests that postural 
automatism is affected in patients 
treated for lower extremity sarcoma. 
 
 
 
 
 
 
 
 
Impairment – Balance 
Patient group – LSS+AMP or AMP – No articles 
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Impairment – Gait     
 Patient group: LSS 
2.   De 
Visser et 
al, 1998 
– A case 
series 
N 
=12 
Mean 
age 38 
years 
AS PMBT or 
locally 
aggressive 
primary 
BT of 
lower 
extremity  
(osteosarco
ma (n=3), 
chondrosar
coma 
(n=6), 
ewing’s 
sarcoma 
(n=2) and 
aggressive 
LSS 
(Excision
+ 
reconstru
ction or 
arthrodes
is) 
Mean 
time 
since 
surgery  
(+/-SD)  
34+/-
21.63 
(range, 
13 to 
59) 
months. 
10 age-
matched 
healthy 
controls, 
mean age  
37.5 
years 
Foot 
switches: 
Treadmill 
walking - At 
patient 
preferred 
speed. 
Footswitches 
in shoe insoles 
to record heel 
strike and heel 
off. 
Gait 
measures: 
Spatio-
temporal 
parameters of 
gait including 
walking speed, 
stride time and 
co-efficient of 
variation. 
Restoration of walking after LSS is 
good in normal walking conditions, 
but patients exhibit lower preferred 
walking speed and higher coefficient 
of variation during normal walking. 
Complex walking with visual and 
cognitive load demonstrated a 
significant decrease in stride time in 
patients, but not in controls. 
Therefore, suggesting gait 
reautomatisation is not complete 2 to 
5 years post-surgery. 
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osteoblasto
ma (n=1)) 
3.  De 
Visser et 
al, 2000 
– A case 
series. 
N=19 Mean 
age  45 
(range 
21 to 
80) 
years 
AS Malignant 
BT of the 
lower 
extremity.  
LSS 
Group 1: 
Knee 
surgery: 
(n=9). 
Group 2: 
Hip 
surgery.  
(n=10) 
 
12 to 
24 
months 
post 
surgery
. 
10 
healthy 
controls, 
mean age 
37 
(range, 
22 to 61) 
years. 
Foot 
switches: 
Treadmill 
walking, with 
footswitches 
in insole of 
shoes. Electro 
goniometers 
to measure 
knee flexion 
angles. 
Gait 
measures: 
Spatio-
temporal 
parameters of 
gait including 
preferred 
walking speed, 
stride time, 
stance time, 
swing time, 
double-limb 
support time, 
and joint 
angles. 
Mean preferred walking speed lower 
in patients compared to controls (0.7 
m/s vs 1.1m/s). Mean stride duration 
longer in patients compared to 
controls (1.5s vs 1.1s). Stance phase 
shorter in the affected leg (57% of 
cycle compared to 62%). No 
difference between hip and knee 
groups in these parameters. Range of 
motion is lower in the knee in patients 
compared with controls in the stance 
phase. Therefore, patient’s gait is 
significantly affected compared to 
healthy control demonstrating an 
incomplete re-organisation of gait. 
4.  Kawai et 
al, 2000 
N=15 Median 
age 24 
AS PMBT of 
the 
LSS - 
Patients 
Median 
time 
20 
healthy 
Foot 
switches: 
Gait 
measures: 
Patients had significantly lower free 
walking velocity and cadence than 
25 
 
– A 
cross-
sectional 
study. 
(range 
16 to 
47) 
years. 
proximal 
femur. 
Tumours 
included 
osteosarco
ma (n=6), 
ewing’s 
sarcoma, 
(n=4), 
chondrosar
coma (n=4) 
and 
malignant 
fibrous 
histiocyto
ma (n=1). 
underwen
t an intra-
articular 
resection 
of the 
hip. The 
median 
length of 
femoral 
resection 
was 21 
(8-28) 
centimetr
es (cms).  
Reconstr
uction 
consisted 
of 1 THR 
and 14 
since 
surgery 
was 27 
(range, 
12 to 
76) 
months. 
controls 
(n=20) 
and 6 
patients 
after  hip 
disarticul
ation 
(n=6)  
 
VA Rancho - 
Footswitch 
Stride 
Analyser ® 
(Rancho Los 
Amigos 
Medical 
Centre , 
California) 
Gait stride 
characteristics 
including 
Free-walking 
velocity, stride 
length, 
cadence,  
gait cycle 
time, double-
limb support 
time, and  
single-limb 
support time. 
controls, but higher than after hip 
disarticulation (walking velocity 63.9 
m/min vs 80.6 and 50.6 respectively; 
cadence 101 steps/min vs 111 and 
81.6 respectively). Asymmetry of 
single-limb support time 
significantly correlated negatively 
with gait velocity and positively with 
net energy cost. Use of a walking aid 
led to less asymmetry but did not 
change velocity because cadence was 
reduced and stride length increased.  
Asymmetry of single-limb support 
time negatively correlated with the 
strength of hip abductors. Walking 
performance of LSS patients was 
better than those who had hip 
disarticulation. 
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Bipolar 
implants. 
5.  De 
Visser et 
al, 2003 
–A case 
series. 
 
N= 
11  
Mean 
age at 
time of 
surgery  
43 
(range 
19 to 
66) 
years. 
AS PMBT of 
the lower 
extremity. 
Tumours 
included 
osteosarco
ma, 
ewing’s 
sarcoma, or 
chondrosar
coma. 
LSS 
(Distal 
femoral 
knee 
prosthesi
s (n=4), 
proximal 
femoral 
hip 
prosthesi
s (n=4), 
and a 
saddle 
prosthesi
s) (n=3) 
Gait 
analysis 
at 5 
months 
postope
ratively
, 
repeate
d at  
7, 9, 
12, and 
15 
months 
No 
control 
group. 
Affected 
and  
unaffecte
d sides 
compared 
Foot 
switches: 
Treadmill 
walking - at 
patient 
preferred 
speed. 
Footswitches 
in the insoles 
of the shoes 
were used to 
record heel 
strike and heel 
off. 
Gait 
measures: 
Preferred 
walking 
velocity, 
stance 
duration, 
swing 
duration, step-
cycle duration, 
stride time. 
Improvement in walking speed and 
asymmetry is seen during recovery 
up to 15 months post operatively. 
However even after the recovery 
period gait control is not optimal, 
which could be attributed to the 
sensory motor losses as a result of 
treatment of the cancer. Patients with 
knee prosthesis had a preferred 
walking speed of  
3.9 km/hr and a stride time of 1.15 s, 
those with a hip prosthesis with 3.4 
km/hr and 1.21 s and those with a 
saddle prosthesis 2.2 km/hr and 1.50 
s respectively. 
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6.  Tsauo et 
al, 2006 -  
A cross-
sectional 
survey 
N = 
20 
Mean 
age (+/-
SD) 
21.7+/-
7.3 
(range 
13 to 
40) 
years 
 
CS+AS PMBT 
(Osteosarc
oma) 
around 
knee, 
located in 
the 
distal 
femur 
(n=13) and 
proximal 
tibia (n=7). 
LSS – 
Wide 
resection 
and 
endoprost
hetic 
knee 
reconstru
ction 
(TKR)  
 
Mean+/
-SD of 
follow-
up was 
3.0+/-
1.6 
(range, 
1 – 5) 
years 
post-
operati
vely. 
20 age 
sex-
matched 
healthy 
control, 
mean age  
21.8+/-
7.3 years. 
 
 
 
Gaitmat: 
GaitMatTMII; 
(Gait MatII 
E.Q. Inc., 
Philadelphia, 
USA), 3.6m in 
length.  
 
Gait 
measures: 
Step velocity, 
step length, 
duration of 
stance phase 
and 
swing phase. 
Walking velocity of patients was 
significantly lower than controls’ (54 
+/- 12m/min vs 72 +/- 6m/min, 
p<0.05). The step length of the 
unaffected side was significantly 
shorter than that of controls and the 
affected side (p<0.05). The stance 
phase of the affected leg was 
significantly shorter than that of 
controls and the unaffected side 
(p<0.05). Conversely, swing phase of 
the affected leg, was significantly 
longer than that of the unaffected 
sides. Patients have achieved an 
acceptable recovery in gait outcomes, 
with some functional limitations. 
7.  Beebe et 
al, 2009 
– A 
N=4 Skeletal
ly 
immatu
CS PMBT in 
the distal 
femur and 
4 LSS - 
Wide 
resection 
Mean 
time 
since 
No 
control 
group. 
Gaitmat: 
GaitRite ®; 
CIR Systems 
Gait 
measures: 
Surgery with a non-invasive 
expandable endoprosthesis produces 
acceptable functional outcomes in 
28 
 
report of 
4 cases. 
 
re 
patients
. At 
time of 
surgery 
– 9 , 9, 
10, 11 
years.  
proximal 
tibia. 
Tumours 
included 
osteosarco
ma (n=3) 
and 
ewing’s 
sarcoma 
(n=1).  
of bone 
sarcoma 
and  
Repiphys
isexpand
able 
endoprost
hesis. 
 
surgery 
31.5 
months.  
Inc, 60 Garlor 
Dr, 
Havertown, 
PA, 19083 
Gait velocity, 
stride time, 
cadence, 
double limb 
support, stance 
phase, swing 
phase, step 
time, step 
length. 
children with PMBT. Patients had 
certain functional limitations 
including reduced ROM and muscle 
strength. Patients also demonstrated 
altered walking and sit-to-stand 
patterns, yet demonstrating a good 
level of coping and emotional 
acceptance after treatments for 
sarcoma. 
8.  Zohman 
et al, 
1997 – A 
cross-
sectional 
study. 
N = 
10 
Mean 
age 
23.8 
(range, 
18 to 
41) 
years 
N/A PMBT 
(Osteosarc
oma) of the 
proximal 
tibia. 
LSS - 
Intra-
articular 
proximal 
tibial 
replacem
ent.  
Mean 
time 
since 
surgery 
6.5 
years. 
A control 
group 
(n=5) of 
above 
knee 
amputees 
including 
trauma 
(n=4) and  
Foot 
switches: 
Stride 
Analyser ®; 
(B&L 
Engineering, 
Santa Fe 
Springs, CA) 
has foot pads 
Gait 
measures: 
Gait velocity, 
stride length, 
cadence, and 
stance time 
symmetry  
Significant difference was only seen 
between cadence after intraarticular 
proximal tibial replacement (112.4 
+/- 10.6 steps/minute) vs control 
group of AMP (110.1 +/- 2.4 steps/ 
minute) (p=0.03). No statistical 
significance was seen between mean 
step velocity after intraarticular 
proximal tibial replacement (79.2 +/- 
29 
 
musculos
keletal 
cancer 
(n=1). 
Mean age 
of 
controls 
were 43.6 
years and 
time 
since 
surgery 
24.1 
years 
worn inside 
shoes, 
containing 
foot switches. 
7.6 m/minute) and control group of 
AMP (71.4 +/- 5.4 m/minute) 
(p=0.06). No significant differences 
were seen between length of stride 
(1.41 +/- 0.13 m vs 1.43 +/- 0.12 m) 
and the symmetry of stance time 
(0.90 +/- 0.07 vs 0.87 +/- 0.11) for 
proximal tibial replacement vs 
control group of AMP. The results 
suggest that LSS for proximal tibia 
leads to a gait comparable with that 
after above knee AMP with a 
prosthesis.   
 
 
Impairment – Gait 
Patient group – LSS+AMP or AMP  – No articles 
 
Participation Restrictions – Physical Activity (PA) 
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Patient group – LSS 
9.  Rosenbau
m et al, 
2008 – A 
cross-
sectional 
study. 
N=22 Mean 
age (+/-
SD) at 
diagnos
is  
26.2+/-
18.4 
(range,
10 to 
73) 
years. 
 
Mean 
age (+/-
SD) at 
assessm
ent 
CS+AS PMBT  
in distal 
femur 
(n=18) and 
proximal 
tibia (n=4). 
Tumours 
included  
osteosarco
ma(n=14) 
chondrosar
coma 
(n=4), 
ewing’s 
sarcoma 
(n=3), and 
malignant 
fibrous 
LSS - 
Intraartic
ular 
resection 
of 
tumour + 
reconstru
ction 
including 
knee 
replacem
ent 
(rotating 
hinge 
(mutars), 
n=20; or 
fixed 
hinge 
Mean 
(+/-SD) 
of 
follow-
up 
7.8+/-
7.9 
(range, 
2 to 39) 
years 
No 
control 
data for 
dynaport. 
 
 
 
 
 
 
 
26 age 
matched 
healthy 
controlfr
om 
which 
SAM 
Activity 
monitors: 
The 
DynaPort ® 
ADL 
monitor;(Mc
Roberts, Den 
Haag, The 
Netherlands) 
worn for 24 
hours 
 
 SAM ® 
Step Activity 
Monitor; 
(Cyma 
Inc., Seattle, 
OR): SAM 
Ambulatory 
(walking) and 
sedentary PA  
in 24 hours 
a. Time spent 
in different 
activities 
b. Movement 
intensity. 
 
Ambulatory 
PA  
a. Volume: 
Daily 
number of 
gcs.  
b. Intensity as 
step 
The highest percentage of PA was 
sitting (54 +/-18%) of the total time 
recorded, followed by standing as 
second highest (27+/-16%), walking 
(10+/-6%), and lying position (8+/-
6%).  During walking, the average 
ambulatory daily PA accumulated to 
4,786+/-1,770 (range 2,045–8,135) 
step cycles, which corresponds to a 
yearly 1.75 million steps. No 
significant correlation was seen in 
between clinical scores and 
ambulatory PA measures. 
The ambulatory PA in patients was 
lower than normal healthy adults, 
however it was comparable to the 
level of activity for other patients, 
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34.5+/-
18.4  
(range, 
16 to 
76) 
years. 
 
histiocyto
ma (n=1). 
 
(Kotz), 
n=2). 
 
 
data was 
collected. 
was worn for 
a week in 
community. 
cycles/minu
te. 
for example, after hip arthroplasty 
reported in previous research. 
10.  Sheiko et 
al, 2012 
– A cross 
sectional 
study 
N=20  Mean 
age 
15.8 
(range,  
11.7 to 
20.8) 
years 
CS PMBT in 
distal tibia 
(n=1), 
proximal 
tibia(n=8), 
distal 
femur 
(n=9) and 
proximal 
femur 
(n=2). 
Tumours 
LSS –  
Implants 
(n=12) 
and 
Allograft
s (n=8) 
 
 
Mean 
time 
since 
surgery 
1.79 
(range, 
0.39 to 
3.82) 
years.  
 
20 age- 
and sex-
matched 
healthy 
controls 
 
Activity 
monitor: 
StepWatch™ 
activity 
monitor (2-
dimensional 
acceleromete
r).  
Monitored 
for 7 
consecutive 
days. 
Ambulatory 
PA: 
a. Volume: 
Total 
stride/day, 
average 
walking 
minutes/ 
day 
b. Intensity: 
Time 
spent/day at 
Patients who had undergone LSS had 
significantly poorer PA sub-scores 
compared to controls. Significant 
differences were seen between LSS 
patients and healthy controls in total 
PA/day (43% vs 48% of total time 
active; P = 0.03), median number of 
total strides/day (4487 vs 7671 
strides; p = 0.001), and time 
spent/day at high activity levels (20 
minutes vs 47 minutes; p = 0.001). 
This demonstrates patients 
32 
 
included 
osteosarco
ma (n=13), 
ewing’s 
(n=5), and  
other 
malignanc
y not 
specified 
(n=2).  
 
 high 
activity 
levels 
c. Others: 
endurance, 
accumulate
d peak 
effort, 
cardio-
vascular 
score, burst 
score, and 
peak score. 
undergoing LSS for a PMBT exhibit 
decreased PA compared to healthy 
age-matched controls. Self reported 
PA questionnaire Activity Scale for 
Kids, Activity scale for kids (ASKp-
38) summary score significantly 
correlated with ambulatory PA 
recorded by the SAM. 
11.  Van deer 
Geest et 
al, 2013 
– A 
prospecti
ve study  
Tumo
ur  
(N= 
43), 
 
Mean 
age 
41.5 
(range, 
19 to 
AS Benign or 
low-grade 
malignant 
bone and 
soft tissue 
tumours  
LSS - 
Local 
excision 
or 
curettage 
and 
Patients 
were 
assesse
d 
before 
surgery 
Controls 
were 
Knee 
arthrosco
py 
Activity 
Monitor: 
An 
actometer 
(Actilog 
V3.0 ®); a 
PA: 
GPA score 
defined as the 
average number 
of accelerations 
in a 5 minute 
In tumour patients, 35% of patients 
were severely fatigued before their 
surgery and 33% post-surgery. 
Significantly higher levels of anxiety 
were reported by tumour patients. 
No significant differences between 
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67) 
years. 
 
 
cryosurge
ry. 
and at 6 
months 
after 
surgery
.  
patients 
(n=24) 
 
Mean age 
of control 
group 
was 43.1 
(range, 
23‑68) 
years. 
 
device which 
senses 
motion and 
attached at 
the ankle for 
12 
consectutive 
days  
duration 
through the day. 
Higher GPA 
scores mean a 
high PA. 
 
tumour patients and controls were 
seen in pain, physical limitations, 
self-efficacy or PA scored captured 
by actometer. Higher pain scores, 
higher anxiety and lower self-
efficacy were significantly 
associated with fatigue severity. In 
controls the percentage of severely 
fatigued patients decreased from 
38% before surgery to 29% 6 
months post-surgery. A high 
numbers of patients were severely 
fatigued in both the tumour and the 
knee arthroscopy groups. Pain, 
anxiety and self-efficacy were seen 
to be the most important factors 
linked to fatigue severity in tumour 
patients prior to surgery. 
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12.  Winter et 
al, 2012 
– A 
longitudi
nal study 
N=20  
 
Mean 
age (+/- 
SD) 
14.4±2.
6 years 
 
CS PMBT in 
the lower 
extremity. 
Tumours 
included 
osteosarco
ma 
(n=15) and 
ewing's 
sarcoma 
(n=5). 
LSS - 
Endopros
thetic 
replacem
ent of the 
affected 
bone 
(proximal 
femur 3, 
distal 
femur 12, 
proximal 
tibia 5) 
6 
weeks, 
3 
months, 
6 
months, 
12 
months, 
and 18 
months 
after 
surgery
. 
20 
healthy 
age- and 
gender-
matched 
controls. 
Activity 
monitor: 
StepWatch™ 
Activity 
Monitor 
SAM ; 
(Ortho- 
Care  
Innovations) 
attached to 
ankle and 
worn for 
seven days.  
Ambulatory 
PA: 
a. Volume in the 
form of the 
number of gcs 
(one gait cycle 
is two steps) 
b. Intensity 
measured as 
gcs/minute. 
Patients with a PMBT in the 
lower limb demonstrated 
significantly lower ambulatory PA 
during the course of active 
treatments.  
 
However these patients recover 
markedly after cessation of 
treatments; reaching 71.9% of 
control group volume of gcs at 18 
months.  Patients with complications 
were slower to recover with some 
limitations seeming to persist at 18 
months post operatively.  
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Participation Restrictions - Physical activity (PA) 
Patient group – LSS+AMP 
13.  Sugiura 
et al, 
2001 – A 
cross-
sectional 
study 
N=56 
Tumo
urs 
includ
ed 
PMB
T 
(n=20
) and 
malig
nant 
soft-
tissue 
tumo
urs 
(n=36
). 
Mean 
age 
45.3 
(range, 
14 to 
85) 
years. 
CS+AS Primary 
musculosk
eletal 
tumours 
(n=56), 
PMBT in 
the distal 
femur 
(n=9), 
proximal 
tibia (n=5), 
proximal 
femur 
(n=3), 
proximal 
fibula 
(n=2), 
All cases 
of BS 
were 
widely 
resected 
(n=20) 
and cases 
of STS 
were 
either 
widely 
resected 
(n=34) or 
marginall
y 
resected 
(n=2).  
Mean 
period 
of 
follow-
up was 
4.3 ± 
2.1 
years, 
20 
healthy 
controls 
of mean 
age 30.4 
years. 
 
Pedometer: 
Omron 
Health 
Counter HJ-
5 
pedometer®; 
(Accuracy 
was 95%): 
Pedometer 
worn for 2 
weeks 
Ambulatory 
PA: 
Volume in the 
form of number 
of steps/day. 
Patients achieved an average daily 
count of 7119 ± 3563 steps (69.8% of 
controls 10,206 ± 1388). BT group 
achieved lesser number of steps/day 
than soft-tissue tumours. Average 
daily step count scores were not 
correlated with ROM. However they 
were correlated with MSTS scores 
(coefficient 0.52). Kotz TKR and 
semiconstrained THR groups had 
lower numbers of steps than other 
groups. Proximal BT nearer to the 
trunk tended to be lower than those 
with tumours in other locations.  
The daily number of steps obtained 
by a pedometer and ADL score 
appear to be clinically as useful as the 
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femoral 
shaft (n=1) 
and STS 
were 
located in 
thigh 
(n=16), hip 
(n=8), knee 
(n=5), calf 
(n=5), 
pelvis 
(n=1), foot 
(n=1).  
 MSTS outcome measure. Thus the 
pedometer is a cost-effective and 
useful objective assessment tool for 
measuring walking ability in 
sarcoma. 
 
14.  Van Dam 
et al, 
2001 – A 
reliability 
and 
N=20 
 
 
Median 
age  
49 
(range, 
18 to 
N/A Malignant 
BT in the 
leg, 
including 
tumours 
located in 
LSS 
(n=12) 
included 
allograft 
(n=1), 
allograft
Median 
time 
since 
surgery 
2 
(range, 
No 
control 
group. 
Activity 
monitor: 
Dynaport 
monitor ®; 
(McRoberts 
BV, 
PA:  
Seven aspects 
were measured 
over a period of 
24 hours which 
were time spent 
The reliability of the monitor was 
satisfactory, with an Intraclass 
correlation coefficient (ICC) from 
0.65 to 0.91 over the function 
measured. 
37 
 
validity 
study. 
69) 
years. 
femur 
(n=12) and 
tibia (n=8). 
+ 
endoprost
hesis 
(knee) 
(n=5), 
Kotz 
prosthesi
s  (n=5) 
and 
mutars 
prosthesi
s (n=1)  
or 
AMP 
(n=8) 
which 
included 
Above 
knee 
1 to 13) 
years. 
 
The Hague, 
The 
Netherlands) 
– Uniaxial 
acceleromete
r. 
 
walking, 
standing and 
sitting (as a 
percentage of 24 
hours), the 
movement 
intensity, and 
also sum of the 
movement 
Intensities. 
There was a significant correlation 
seen between ‘time spent walking’ 
and the MSTS scores and also the 
Rand-36  
scores. A significant association was 
also seen between ‘movement 
intensity during walking’ and 
MSTS. 
Results demonstrate promising 
reliability and validity of the monitor 
to clinically measure PA objectively 
in patients treated for a lower 
extremity malignant BT. 
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AMP 
(n=3), 
Knee 
disarticul
ation(n=3
) and Van 
Nes 
rotationpl
asty 
(n=2). 
15.  Hopyan 
et al, 
2006 – A 
retrospect
ive 
cohort 
study 
N = 
54 
(45 
compl
eted 
study 
and 9 
lost to 
Mean 
age of 
patients 
who 
complet
ed the 
study 
(n=45) 
CS - 
Mean age 
of these 
patients 
at 
diagnosis   
11.9 +/-
4.2 
PMBT of 
the lower 
extremity. 
 
LSS 
(n=20) 
and 
Above 
knee 
AMP 
(n=19), 
Rotationp
lasty 
Mean 
follow-
up time 
of 
study 
patients 
(n =45) 
was 
13.9+/-
No 
control 
group. 
Activity 
monitor: 
Uptimer 
device ®; 
(National 
Aging 
Research 
Unit, 
Victoria, 
PA: 
PA was 
measured using 
the uptime 
device 
“amount/percent
age of time an 
individual 
spends in the 
SF-36 (36-Item Short Form Survey) 
and uptime measured by the activity 
monitor, were similar between 
groups. Uptime had higher values in 
patients with rotationplasty, 
although statistical comparisons 
were not feasible.  
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follo
w-up) 
26+/-7 
(range, 
10 to 
39) 
years. 
(range, 1-
19) years 
(n=5) and 
below 
knee 
AMP 
(n=1). 
5.7 (5-
26) 
years 
Australia), 
an activity 
monitor. 
upright position 
(standing or 
walking)” also 
termed as 
“uptime 
16.   Winter et 
al, 2009 
– A 
prospecti
ve study. 
N= 
23 
lower 
extre
mity 
BT 
(Total 
29 
patien
ts 
with 
BT in 
upper 
extre
Median 
age (+/- 
SD) of 
all BT 
patient 
(n=29) 
15.1+/-
3.2 
years. 
CS 80 patients 
including 
BT (n=29), 
leukaemia 
(n=20) , 
lymphoma 
(n=15), 
brain 
tumours 
(n=12), 
germ cell 
tumours 
(n=3), and  
LSS+AM
P 
 
13 out of 
23 lower 
extremity 
BT 
patients 
were 
operated 
as 
follows: 
Prostheti
c 
2 
groups 
of BT 
patients
: 
 
16 
patients 
were 
measur
ed pre-
operati
vely  
 
45 
healthy 
control 
who were 
age and 
genderma
tched to 
patients 
for 
distributi
on and 
body 
mass 
index 
Activity 
monitor: 
StepWatch™ 
Activity 
Monitor 
SAM; 
(OrthoCare 
Innovations, 
Seattle, WA) 
- A 
uniaxial 
acceleromete
r. 
Ambulatory 
PA: 
a. Volume 
measured 
as gcs/ day. 
b. Intensity 
measured 
as gcs/ 
minute. 
Pediatric cancer patients (2,787 
gcs/day) scored significantly lower  
than healthy controls (8,096 gcs). 
Patients were more physically 
activity at home (3,185 gcs, 40% of 
controls) rather than inpatient stays 
(1,830 gcs, 23% of controls). 
Patients with BT exhibited lower PA 
scores than those with leukemia with 
respect to the volume (1,849 gcs vs. 
2,992 gcs) 
and also the intensity of PA.  
Patients with BT exhibited 16% of 
the PA when compared to controls 
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mity 
(n=6) 
and 
lower 
extre
mity 
(n=23
) 
neuroblast
oma (n=1). 
limb 
replacem
ent 
(n=7),  
AMP 
(n=3), 
and 
excision 
(n=3) 
13 
patients 
on an 
average 
of 12 
weeks 
post-
operati
vely. 
 
(BMI), 
height 
and 
weight 
comparab
le to 
patients. 
worn on 
ankle 
during inpatient stay and 27% of the 
PA compared to controls during 
their home stay. Patients with 
leukaemia achieved higher 
percentage of PA in both inpatients 
and home when compared to BT, 
however this difference was not 
significant. Patients with BT seem to 
be at a substantially high risk of 
reduced PA. This indicates 
individualised rehabilitation 
interventions need to be delivered 
during treatment to improve 
outcomes. 
17.  Bekkerin
g et al, 
2011 – A 
cross -
N = 
82 
 
Mean 
age (+/- 
SD) at 
time of 
surgery 
CS PMBT 
around 
knee, 
located in 
the  
LSS 
(n=39) 
consistin
g of 
Mean 
time 
since 
surgery 
was 
No 
control 
group 
Activity 
monitor: 
Actilog ® 
V3.0; 
Radboud 
PA: 
a. GPA score 
defined as the 
average number 
of accelerations 
Significantly better scores were seen 
in the LSS group for the timed up 
and down stairs (TUDS) and various 
walking activities test (VWA) as 
compared to the AMP group. No 
41 
 
sectional 
study 
14.2+/-
4.1 
years. 
 
Mean 
age (+/- 
SD) at 
assessm
ent was 
16.9 +/-
4.2 
years. 
proximal 
femur 
(n=54) and 
distal tibia 
(n=28). 
Tumours 
included 
osteosarco
ma and 
ewing’s 
sarcoma. 
allograft 
(n=24),  
endoprost
hesis 
(n=15) 
Ablative 
surgery 
(n=43) 
consistin
g of 
AMP 
(n=27) 
and  
Rotationp
lasty 
(n=16) 
2.8+/- 
1.6 
years. 
University 
Nijmegen 
Medical 
Centre, 
Nijmegen, 
The 
Netherlands) 
– Placed on 
ankle of non-
affected limb 
and worn for 
7 
consecutive 
days. 
in a 5 minute 
duration 
through the day, 
and  
b. Average peak 
amplitude and 
duration 
(average peaks 
is the number of 
high peak 
accelerations in 
a 5 mins 
duration, during 
the day and is a 
reflection of 
intensity of PA) 
of accelerations  
significant differences were seen 
between LSS and AMP for any of 
the Actilog PA measures. 
In long term (from 1 to 5 years), 
post-surgery due to a bone cancer in 
paediatric population and 
adolescents, there is no significant 
difference seen between patients 
having a LSS and AMP with respect 
to overall physical functioning  and 
PA, apart from going up and down 
stairs and few walking activities. 
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18.  Bekkerin
g et al, 
2012 – A 
prospecti
ve 
longitudi
nal study  
 
N=44 
44 
patien
ts 
were 
recrui
ted 
into 
study, 
out of 
which 
24 
patien
ts 
compl
eted 
study  
Mean 
age (+/- 
SD) at 
time of 
surgery 
14.9+/- 
4.8 
years 
CS PMBT 
around 
knee, 
located in 
distal 
femur 
(n=32) and 
proximal 
tibia 
(n=12). 
Tumours 
included 
osteosarco
ma (n=41) 
and 
ewing’s 
sarcoma 
(n=3). 
LSS 
(n=27) 
including 
allografts 
(n=8), 
prosthesi
s (n=19), 
Ablative 
surgery 
(n=17) 
including  
AMP 
(n=10) 
and 
Rotationp
lasty 
(n=7) 
At 3, 6, 
9, 12, 
18, and 
24 
months 
post-
surgery
. 
No 
control 
group. 
Activity 
monitor: 
Actilog ® 
V3.0; 
Radboud 
University 
Nijmegen 
Medical 
Centre, 
Nijmegen, 
The 
Netherlands)
.– Placed on 
ankle of non-
affected limb 
and worn for 
7 
consecutive 
days. 
PA: 
a. GPA score 
defined as the 
average number 
of accelerations 
in a 5 minute 
duration 
through the day, 
and  
b. Average peak 
amplitude and 
duration of 
accelerations  
Over the first year post-operatively, 
patients demonstrated significant 
improvements in quality of life 
(QoL), physical ability and activity 
levels as measured by Baecke 
questionnaire. Over the second year 
after surgery, the improvements 
were present but less pronounced. 
No difference in PA was detected by 
the Actilog activity monitor.  
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Abbreviations: 
CCS – Childhood cancer survivors 
AS – Adult cancer survivors 
LSS – Limb Sparing Surgery 
AMP – Amputation 
vs  - Versus 
PMBT – Primary malignant bone tumour 
BT – Bone tumour 
STS – Soft tissue sarcoma 
TKR – Total knee replacement 
THR – Total hip replacement 
MSTS - Musculoskeletal Tumour Society Rating Scale 
ACP - Displacement of amplitude of the centre of pressure 
VCP - Velocity of the centre of pressure 
PA – Physical Activity 
gcs  – Gait cycles 
GPA – General physical activity 
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ADL - Activities of daily living   
SAM - Step activity monitor 
N/A – Not available 
m/s = metre per second 
m/min – metre per minute 
km/hr – kilometre per hour 
s  = second 
m = metre 
SD – Standard deviation 
/day – per day 
/min  per minute 
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Table 3: Validity and Reliability of measures in the literature: Reference Values for patients treated for Musculoskeletal Cancer 
 
S
r 
N
o
. 
Article Comparison to 
controls (Form of 
construct validity – 
divergent validity) 
Comparison 
between sub-
groups of 
patients 
(Divergent 
validity) or 
relations 
between 
demographics, 
clinical 
characteristics 
and outcome 
Convergent 
validity) 
Comparison 
between different 
testing conditions 
(Form of construct 
validity) 
Association 
with 
established 
validated 
measures in 
Sarcoma 
(Form of 
construct 
validity – 
convergent 
validity) 
Comp
arison 
with a 
gold 
stand
ard 
(Crite
rion 
validit
y) 
 
 
 
 
Reliability 
(Test-retest 
validity or 
intra-tester 
or inter-
tester 
reliability) 
Sensitivity 
/Responsiveness  
to change 
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Balance – LSS   
1.  De 
Visser 
 et al, 
2001 
 
Upright Standing: 
Eyes-open: 
 No significant 
differences in 
ACP and VCP 
measures between 
patients and 
controls (p>0.05).  
Eye-closed: 
 Both patients and 
controls have an 
increased VCP 
with eyes closed, 
in comparison to 
eyes open 
  Upright Standing: 
Eyes-open: 
 No significant 
differences in 
ACP and VCP 
measures 
between 
patients and 
controls 
(p>0.05).  
Eyes-closed: 
 Closing the 
eyes increases 
ACP and VCP 
in patients in 
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(p<0.05). 
However, 
displacement of 
CP in eyes closed 
condition, was 
smaller for 
patients than 
controls (p<0.05). 
Dual-Task: 
 Only patients 
showed a 
significantly 
higher ACP 
(4.5+/-0.8 mm) 
when compared to 
normal standing 
the anterior-
posterior 
direction, when 
compared to 
eyes-open 
normal 
standing.  
Dual-Task: 
 When the 
auditory stroop 
task was 
performed, only 
patients showed 
a significantly 
higher ACP 
(4.5+/-0.8 mm) 
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(2.9+/-0.4 mm) 
and VCP (18.6+/- 
3.0 mm/sec) when 
compared to 
normal standing 
(11.9+/-1.0 
mm/sec) when the 
auditory stroop 
task was 
performed, 
however patients 
and controls were 
not significantly 
different. 
 
 
when compared 
to eyes-open 
normal 
standing (2.9+/-
0.4 mm) and 
VCP (18.6+/- 
3.0 mm/sec) 
when compared 
to eyes-open 
normal 
standing 
(11.9+/-1.0 
mm/sec). 
 
 
 
49 
 
Standing on balance 
board: 
Eyes open: No 
significant differences 
were seen between 
patients and controls. 
 
Eyes-closed and 
Dual-task: 
 A significant 
difference in VCP 
was seen for both 
groups with eyes 
closed condition 
and also under 
dual-task 
Standing on 
balance board: 
Eyes-Closed and 
Dual-task: 
 A significant 
difference in 
VCP was seen 
in patients with 
eyes closed 
condition and 
also under dual-
task conditions; 
(patients, 
80.1+/-12.9 and 
23.6+/- 3.4 
mm/sec). 
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conditions 
(controls, 23.2+/-
3.3 and 14.9+/-2.9 
mm/sec; patients, 
80.1+/-12.9 and 
23.6+/- 3.4 
mm/sec). 
 
Gait – LSS 
2.  De 
Visser et 
al, 1998 
 
 Patients walked 
with a lower 
preferred walking 
speed (2.4 km/hr) 
than controls (3.8 
km/hr) and 
showed a higher 
 There was 
no relation 
between 
sub-groups 
such as 
tumour type, 
surgery type 
 In complex 
walking such as 
dual task or 
visual 
restrictions, 
patients showed 
a significant 
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co-efficient of 
variation of stride 
time than the 
normal subjects, in 
normal and 
complex walking.  
 When walking 
with constraints, a 
significant 
reduction in stride 
time was seen in 
patients, but not in 
normal subjects, 
(p<0.05). Controls 
did not show any 
significant 
and location 
of tumour 
with the 
level of 
visual and 
cognitive 
dependency. 
reduction in 
stride time 
compared to 
normal walking 
conditions. 
(p<0.05) 
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differences in the 
three conditions.  
3.  De 
Visser et 
al, 2000 
 The preferred 
speed of walking 
in LSS patients 
(0.7+/-0.3 m/s) 
was lower than 
that in controls 
(1.1+/-0.08 m/s).  
 The mean stride 
duration in 
patients (1.5+/-0.6 
s) was longer than 
controls (1.1+/-
0.06 s)(p<0.05).  
There were no 
significant 
differences 
between gait 
parameters in 
hip and knee 
group (p<0.05) 
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 The stance phase 
of affected leg was 
shorter and of non-
affected leg was 
longer. The stance 
phase of non-
operated kegs in 
patients was 
longer than 
controls. All 
patients treated for 
LSS showed a 
reduced knee 
flexion during 
stance phase in the 
operated leg.  
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4.  Kawai et 
al, 2000 
 The patients 
walked with a 
significantly less 
cadence and stride 
time compared to 
controls (p<0.05). 
 Patients had a 
significantly 
shorter single limb 
support time on 
the affected side 
(0.42 ± 0.06), 
compared to the 
unaffected side 
(0.52 ± 0.07) 
(p<0.05). The 
 Patients with 
proximal 
femoral 
replacement 
had a 
superior gait 
than patients 
with hip 
disarticulatio
n in 
characteristi
cs listed 
below. 
Patients with 
proximal 
femoral 
 Patients who 
used a cane, 
walked with 
less cadence 
longer stride 
length, and 
with walking 
velocity not 
significantly 
changed. The 
single-limb 
support times 
were prolonged 
and asymmetry 
was 
 Free-
walking 
velocity 
was 
negatively 
correlated 
with the 
net energy 
cost  
(r = -0.55,  
p = 0.05). 
 Free-
walking 
velocity 
and 
asymmetry 
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asymmetry 
difference was 
0.09 seconds (0.01 
to 0.22). 
replacement 
had a 
significantly 
higher 
walking 
velocity and 
asymmetry 
than patients 
with hip 
disarticulatio
n (p<0.05). 
In addition, 
energy cost 
and 
asymmetry 
of walking 
significantly 
decreased. 
of the 
single-limb 
support 
time 
demonstrat
ed a 
significant 
negative 
co-relation 
(r = -0.67, 
p =0.006). 
 Asymmetr
y of  
single-limb 
support 
time and 
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was higher 
in patients 
with hip 
disarticulatio
n compared 
to those who 
had a 
proximal 
femoral 
replacement.  
strength of 
abductor 
muscles 
demonstrat
ed a weak 
negative 
correlation  
(r = -0.62,  
p = 0.05).  
 No 
significant 
correlation 
was seen 
between 
gait 
outcomes 
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in patients 
and length 
of the 
proximal 
femur 
resected. 
5.  De 
Visser et 
al, 2003  
 
  Patients 
treated with 
a knee 
prosthesis 
walked at a 
speed of 
3.9+/- 0.15 
km/hr and 
stride time 
During the 
recovery period, 
patients step cycle 
duration were 
reduced by 
complex add-ons 
such as dual task 
and visual 
restriction while 
walking. 
   Patients have an 
improvement in 
the gait outcome 
such as step-cycle 
duration, walking 
speed, gait 
symmetry over 
time and with 
rehabilitation: 
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of 1.15+/-
0.05 sec.  
 Patients with 
a hip 
prosthesis 
walked with 
a preferred 
speed of 
3.4+/- 0.23 
km/hr and a 
step-cycle 
duration 
of 1.21+/-
0.07 sec 
after 15 
months.  
 
 
 Walking 
speed was 
seen to 
increase from 
2.1+/-
0.9km/hr to 
3.5+/-0.3 
km/hr during 
the end of 
rehabilitation.  
 Step-cycle 
duration 2 +/-
1.04 sec was 
significantly 
decreased to 
1.18+/- 0.106 
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 Patients with 
saddle 
prosthesis 
walked at a 
speed of 2.2 
+/- 1.1 
km/hr and a 
stride time 
of 1.50+/-
0.33 sec. 
sec at end of 
rehabilitation.  
 A slight 
improvement 
of gait 
symmetry was 
observed, 
with some 
gait 
asymmetry 
still persistent  
        after 15 
months.  
6.  Tsauo et 
al, 2006 
 
 Patients walking 
velocity were 
54+/-12m/min, 
  The ratio of 
quadriceps 
strength of 
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and controls’ was 
72+/-6m/min 
(p<0.05). 
 The step length 
of patient’s 
unaffected  side is 
significantly 
shorter than 
controls and 
affected side 
(Affected side was 
115.8+22.2% of 
unaffected limbs’)  
(p<0.05).  
 The stance phase 
of patients’ 
operated by 
normal knee, 
and isometric 
strength of 
hamstring by 
quadriceps 
ratio of 
operated knee 
was correlated 
significantly  
to the 
difference of 
stance-phase 
duration of 
both sides 
(p<0.05). 
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affected leg was 
significantly 
shorter than that of 
controls and 
unaffected side 
(88.2+5.9% of 
unaffected 
limbs’)(p<0.05). 
 Conversely, swing 
phase of patients’ 
affected leg, was 
significantly 
longer than that of 
their unaffected 
sides 
(127.3+22.1% of 
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unaffected limbs’) 
(p<0.05). 
7.  Beebe et 
al, 2009  
 
Aspects of gait 
reduced were: 
 Gait velocity 
(range, 86.8 –
108.4cm/s; 
controls from 
literature 
128cm/s), 
 Stride length 
(range, 101.68–
120.04cm in the 
affected limb; 
102.07–114.19cm 
in the unaffected 
  MSTS gait 
sub-component 
were reported 
as 3/5 
and total 
MSTS score as 
23.5/30) 
 
 
Only scores 
were stated. 
No formal 
comparisons 
have been 
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limb; controls 
from literature 
128cm), and 
 Cadence (range, 
87.9 –113.5 
steps/min; controls 
from literature is 
117 steps/min). 
 Double-limb 
support was higher 
in patients (range, 
26.0–32.3% Gait 
Cycle (GC) in the 
affected limb, 
26.8–32.4% GC 
compared to 
made therefore 
no testing of 
validity in this 
section. 
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unaffected limb; 
values for controls 
from literature is 
20% GC).  
 Stance phase was 
greater in all 
patients in the 
unaffected limb 
(range, 59.8–
67.7% GC; values 
for controls from 
literature is 60% 
GC) but only in 
half of the patients 
in the affected 
limb (range, 58.1–
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67.8% GC, values 
for controls from 
literature is 60% 
GC).  
 Swing phase, step 
length, and step 
time were higher 
in the affected 
limb compared to 
unaffected limb 
8.  Zohman 
et al, 
1997 
 
  No statistical 
significance 
was seen 
between 
mean step 
velocity 
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after 
intraarticular 
proximal 
tibial 
replacement 
(79.2 +/- 7.6 
m/min) and 
control 
group of 
amputees 
(71.4 +/- 5.4 
m/min) 
(p=0.06) 
 Significant 
difference 
was seen 
67 
 
between 
cadence 
after 
intraarticular 
proximal 
tibial 
replacement 
(112.4 +/- 
10.6 
steps/minute
) vs control 
group of 
amputees 
(100.1 +/- 
2.4 
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steps/minute
) (p=0.03). 
 No 
significant 
differences 
were seen 
between 
length of 
stride (1.41 
+/- 0.13 m 
vs 1.43 +/- 
0.12 m) and 
the 
symmetry of 
stance time 
(0.90 +/- 
69 
 
0.07 vs 0.87 
+/- 0.11) for 
proximal 
tibial 
replacement 
vs control 
group of 
amputees. 
 
Physical Activity – LSS 
9.  Rosenba
um et al, 
2008 
 
Ambulatory 
(walking) and 
sedentary PA: 
Volume:  
 Patients performed 
the predominant 
Volume: 
 Data 
collection 
duration was 
negatively 
Volume: 
On 
weekends, 
patients 
walked only 
95% of the 
Volume: 
 A low 
correlation was 
observed 
between SAM 
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daily activity of 
sitting (54+/-18% 
of the time 
recorded) 
compared to 
control(42%), then 
followed by 
upright standing 
(27+/-16%) 
compared to 
controls (41%), 
followed by 
ambulation (10+/-
6%) compared to 
controls (11%), 
and lying (8+/-
correlated 
with 
Body mass 
index (BMI) 
(p<0.01). No 
correlations 
were seen 
between PA 
and the 
duration of 
follow-up. 
 The gcs did 
not correlate 
with 
patient’s age 
but 
steps 
achieved 
during 
weekdays. 
 
and MSTS 
(p=0.2). 
 A poor 
correlation 
coefficients for 
locomotion vs 
MSTS or TESS, 
and also between 
SAM and TESS 
score. 
 No significant 
relations between 
gait analysis in 
laboratory and 
Activities of 
daily living 
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6%) compared to 
controls (4%). 
 The ambulatory 
activity level in 
patients was 
significantly lower 
(4,786+/-1,770 
cycles/day) than 
normal healthy 
adults (6,517+/-
1,489 cycles/day) 
(p=0.01), however 
it was comparable 
to the level of 
activity for other 
patients. For 
demonstrate
d marked 
subject 
differences 
(range 
2,045–
8,135). 
 The mean 
movement 
intensity 
during 
walking 
activity was 
2.4+/-0.4 
m/s2 . This 
did not 
(ADL) 
monitoring in a 
sub-group of 
patients. 
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example, with hip 
arthroplasty 
reported in 
literature. 
Intensity: 
 Healthy controls 
spent more time in 
higher intensity 
activities (absolute 
values). No 
significance 
testing performed. 
correlate 
with the age, 
weight or 
BMI. 
 No 
significant 
differences 
were seen 
between 
location of 
tumour in 
proximal vs 
distal femur 
(p>0.05). 
10.  Sheiko et 
al, 2012  
Ambulatory PA:   Volume:    
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 Patients who 
underwent LSS had 
significant reduced 
PA levels when 
compared to healthy 
controls: 
Volume: 
 There were 
significant 
differences 
between patients 
who had 
undergone LSS 
and healthy 
controls in total 
PA/ day (43% vs 
Self-reported PA 
questionnaire ASKp-
38 summary score 
significantly 
correlated with step 
watch average 
strides/day (r=0.50, 
p<0.05), ASKp-38 
locomotion sub-
score correlated 
significantly with 
step watch average 
strides/day (r= 0.63, 
p<0.01) and 
StepWatch % time 
active r=0.56, 
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48%; P = 0.03), 
the median value 
of total strides/day 
(4487 vs 7671 
strides; p = 0.001). 
 Average walking 
minutes/day in 
LSS patients were 
370 (211 - 587) as 
compared to 
healthy controls as 
438 (275-518) 
(p=0.05) 
Intensity: 
 Time spent/day at 
high activity levels 
p<0.05). 
Correlations were 
tested using 
spearman’s 
correlation. 
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(20 minutes vs 47 
minutes; p = 
0.001). 
Others: 
 Significant 
differences were 
also seen between 
patients treated for 
LSS and healthy 
controls for 
endurance (18 vs 
28, p<0.001), 
accumulated peak 
effort (22 vs 33, 
p<0.001), cardio-
vascular score (27 
76 
 
vs 39, p<0.001), 
burst score (41 vs 
54, p<0.001) and 
peak score (55 vs 
66, p<0.001).  
11.  Van deer 
Geest et 
al, 2013 
 
PA: No significant 
differences between 
change in PA scores 
between tumour 
patients and controls 
(arthroscopy patients). 
(No reference values 
mentioned) 
  No significant 
correlation between 
fatigue and PA 
scores.  
  Absolute values 
of actometer 
scores increased 
over time from 
pre-surgery to 
recovery. 
However 
significance tests 
were not 
performed due to 
77 
 
a small sample 
size. 
12.  Winter et 
al, 2012 
Ambulatory PA: 
Patients achieved 
significantly lesser 
volume (gcs/day) and 
time spent in moderate 
intensity (time spent 
in >50 gait 
cycles/min)) of PA 
than controls at all 
time points (p<0.001).  
Volume: 
 Controls achieved 
7,100±1,918 
gcs/day, whereas 
Significant 
differences in 
volume and 
intensities were 
observed 
between patients 
with and 
without 
complications at 
various time 
points. 
Volume: 
 Differences 
were 
Volume and 
Intensity: 
 The 
lowest 
scores for 
volume 
and 
intensities 
for PA 
were seen 
at 6 
weeks 
post-
   Volume and 
Intensity: 
 A continuous 
increase in 
absolute 
values of 
volume and 
intensity of 
PA was 
observed at 
each follow-
up 
 However 
significant 
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patients achieved 
770±793gcs/day at 
6 weeks, 
1,847±1,047 at 3 
months, 
2,351±1,842 at 6 
months, 
3,917±1,703 at 12 
months, 
5,107±1,600 at 18 
month, which was 
significantly 
different from 
controls at each 
time point 
(p<0.001). 
observed 
between 
sub-groups 
such as 
patients with 
and without 
complication
s 6 months 
post 
operatively 
(599 vs. 
2,794 gcs in 
a day) which 
continues to 
exist 12 
months post-
operativel
y. 
 Significa
nt 
increases 
in the 
volume of 
ambulator
y activity 
were seen 
after 
cessation 
of therapy 
(chemoth
erapy) at 
6 months 
increases were 
only seen 
when 
comparing the 
first 
measurement 
after surgery 
to the 12 
month and 18-
month follow-
ups (p<0.003). 
 No significant 
differences 
observed 
between other 
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Intensity:  
 Controls spent 
27.6±14.5 minutes  
at moderate 
intensity (time >50 
gait cycles/min), 
whereas patients 
spent 1.1±2.1 
minutes at 6 weeks 
, 2.2±5.9 at 3 
months, 3.1±7.0 at 
6 months, 
10.5±13.5 at 12 
months and 
15.2±16.1 at 18 
months, which 
operatively, 
with 3,279 
vs. 3,826 
gcs/ day. At 
18 months 
post-
operatively, 
no 
significant 
differences 
were present 
with regards 
to volume of 
PA. 
Intensity: 
post-
operativel
y, 
however 
intensity 
showed 
minor and 
no 
significan
t changes. 
Increase 
in 
intensity 
to higher 
levels 
was seen 
measurements
. 
80 
 
was significantly 
different from 
controls at each 
time point 
(p<0.001).   
 Therefore patients 
did not reach level 
of healthy controls 
even at 18 months 
post-operatively. 
 
 Patients with 
complication
s did not 
perform any 
moderate 
intensity 
activities at 
12 months, 
whereas 
patients with 
complication
s achieved 4 
minutes/ 
day. At this 
moderate 
level 
in longer 
term 
follow-
up. 
 12 
months 
post-
operativel
y patients 
significan
tly 
improved 
volume of 
activity 
compared 
to the 
81 
 
differences 
were more 
pronounced 
at 12 months 
(0.3 – 12.6 
minutes), 18 
months (3.7 
vs 18.9 
minutes) 
post-
operatively. 
treatment 
phase, 
with no 
major 
improve
ments in 
moderate 
intensity 
levels of 
PA. 
 
Physical Activity – LSS + AMP 
13.  Sugiura 
et al, 
2001 
 
Ambulatory PA: 
Volume: 
56 patients achieved 
an average daily step 
Volume: 
 Average daily 
step count of 
the BT and 
 Volume: 
 Average daily 
step count was 
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count of 7119 ± 3563 
which as 69.8% of 
controls  
(10,206 ± 1388)  
 
 
soft-tissue 
tumour 
clinical 
groups were 
6001 ± 2684 
and 7758 ± 
3835 steps 
(which was 
58.8% and 
76.0% of the 
controls, 
respectively). 
 The BT group 
demonstrated 
a significantly 
lower average 
not correlated 
with ROM. 
 Average daily 
step count was 
significantly 
correlated with 
MSTS 
(coefficient 
0.52, P<0.001). 
A relation value 
was also 
determined as 
The number of 
steps = 0.001 X 
MSTS score ± 
14.499 
83 
 
daily step 
count 
compared to 
the soft-tissue 
tumour (p < 
0.05)  
 Kotz TKR 
and 
semiconstrain
ed THR 
groups, 
achieved 
significantly 
lower number 
of steps than 
other groups 
 The hip 
abductors and 
hip flexors 
strength were 
more closely 
correlated 
(measured by 
correlation rate) 
with daily step 
count than with 
knee extensors 
and knee flexors 
strength. 
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such as 
resection 
without 
reconstruction 
of bone (n = 
30), above-
knee 
AMP (n = 4), 
total femur 
autoclaved 
bone  
(n = 5), 
autograft (n = 
2), heat-
treated bone 
(n = 5), 
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replacement 
(n = 1). (No 
values for 
each group, 
only 
represented 
graphically) 
 For patients 
with a tumour 
more 
proximally 
(closer to the 
trunk) tended 
to achieve 
lower steps 
than those 
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with tumours 
in other 
locations, and 
this was 
mainly seen in 
BT group. 
14.  Van 
Dam et 
al, 2001. 
 
 PA: 
Volume: 
 The LSS 
(n=12) and 
AMP (n=8) 
group were 
both similar 
on MSTS, 
TESS, 
Baecke, Euro-
 Volume: 
 There was a 
significant 
correlation 
seen 
between 
‘time spent 
walking’ and 
the MSTS 
scores and 
  The test-
retest 
reliability 
(n=17) of 
the 
monitor 
was 
satisfacto
ry, with 
an ICC  
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QOL and 
Rand-36 
scores. 
Percentage of 
time spent 
walking (in 24 
hours) in 
whole group 
was 
5.1(2.37)%. In 
LSS group 
was 5.6 
(2.02)% and 
in AMP was 
4.3 (2.78). 
Intensity: 
also the 
Rand-36  
scores.  
Intensity: 
 A significant 
association 
was also 
seen 
between 
‘movement 
intensity 
during 
walking’ and 
MSTS. 
 
from 0.65 
to 0.91 
over the 
function 
measured. 
ICC for 
individual 
aspects of 
function were 
as follows: 
Volume: 
 Time 
spent in 
walking 
task ICC 
= 0.65, 
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 Walking 
intensities 
were 2.1 
(0.39) m/s2 in 
whole group. 
LSS patients 
scored 
2.26(0.43) 
m/s2 and 
AMP group 
scored 1.9 
(0.15) m/s2. 
 However no 
significant 
differences 
were seen 
Time in 
standing 
= 0.83, 
Time in 
sitting = 
0.75. 
Intensity: 
 Movemen
t intensity 
(m/s2) 
Walking 
= 0.91 
Standing 
= 0.69 
Sitting = 
0.79 
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between the 
LSS and AMP 
groups with 
respect to 
‘time spent in 
certain 
activities’ and 
‘movement 
intensities’ 
(p>0.05). 
 
Total 
(walking, 
standing 
or sitting) 
0.91 
15.  Hopyan 
et al, 
2006 
 PA: 
Volume: 
 Uptime 
(expressed in 
percentage) in 
 Volume: 
Significant 
differences were 
seen between 
LSS and AMP 
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LSS group 
(n=15) was 
24.0+/-9.2 
(range, 10-
40), Above-
knee AMP 
group (n=15) 
was 26.7+/-
7.3 (range, 
18-40), 
rotationpstlast
y group (n=5) 
was 30.1+/-
9.2 (18-43) 
and below 
groups, using 
TESS (p=0.06) 
and MSTS 
(p<0.0001). 
However no 
significant 
differences were 
seen between 
LSS and AMP 
in uptime 
(p=0.39) 
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knee AMP 
was 26 (n=1)  
 Uptime 
measured by 
the activity 
monitor, were 
similar 
between 
groups. 
Uptime had 
higher values 
in patients 
with 
rotationplasty, 
although 
statistical 
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comparisons 
were not 
feasible. 
16.  Winter et 
al, 2009 
 
Ambulatory PA: 
Volume: 
 Patients with BT 
exhibited 1275+/-
1105, median 943 
gcs/day, which 
was 16% of the 
PA when 
compared to 
controls (8096+/-
2951, median 
7438 gcs/day) 
during inpatient 
Volume: 
 Patients with 
BT exhibited 
lower volume 
of PA scores 
than those 
with leukemia 
(1,849 gcs vs. 
2,992 gcs) 
However no 
statistical 
significant 
differences 
Volume: 
Significant 
differences 
between inpatient 
(1275+/-1105, 
median 943 
gcs/day) and 
home stays 
(2145+/-1422 
median 1490 
gcs/day) were 
seen in BT 
patients. During 
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stay and achieve 
2145+/-1422 
median 1490 
gcs/day which is 
27% of the PA 
compared to 
controls during 
their home stay 
(p<0.001). 
Intensity: 
 Patients in the BT 
group spent a 
lesser percentage 
of time at high 
intensity activities 
during in patient 
seen in both 
settings. 
Intensity: 
 Percentage of 
time on high 
intensity 
activities were 
6.1+/-3.7, 
median 5.7 
compared to 
BT patients 
(3.5+/-4.7, 
median 2.1). 
However 
though clearly 
reduced 
in stay patients 
achieved 59% of 
the PA, they 
achieved at home 
(p<0.001).  
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stay (3.5+/-4.7, 
median 2.1) when 
compared to 
controls (14.7+/-
7.2, median 12) 
(p<0.001) and 
4.2+/-5.5, median 
2.9 during home 
stay, which was 
significantly lower 
than controls 
(14.7+/-7.2, 
median 12) 
(p<0.05) 
intensities of 
activities in 
bone cancer 
patients, there 
were no 
statistically 
significant 
differences 
seen between 
the 
leukaemia’s 
and BT 
patients. 
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17.  Bekkerin
g et al, 
2011 
 
 PA: 
 GPA values 
for LSS 
(n=30) group 
was 93.9 
(25.4) and for 
AMP (n=36) 
group was 
94.8 (29.7). 
No significant 
differences 
between 
groups. 
 Average 
peaks were 
142.3 (14.7) 
 Significantly 
better scores 
were seen in the 
LSS group for 
the timed up and 
down stairs 
(TUDS) and 
various walking 
activities 
(VWA) test as 
compared to the 
AMP group. 
However no 
significant 
differences were 
seen between 
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for LSS and 
143.8 (21.9) 
for AMP. No 
significant 
differences 
between 
groups. 
LSS and AMP 
for any of the 
PA measures 
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18.  Bekkerin
g et al, 
2012 
 
   PA: 
PA was 
measured using 
Baecke 
questionnaire 
and Actilog 
activity monitor. 
A significant 
increase in 
activity levels 
between 3 to 12 
months (p < 
0.01) was 
detected by the 
Baecke 
questionnaire. 
  GPA and average 
peak of 
accelerations 
measured with 
Actilog activity 
monitor did not 
show statistical 
significant 
differences at 
various time 
points. 
 GPA scores: 
At 3 months 
81+/-6.8, 6 
months 87+/-
6.8, 12 
98 
 
However the 
GPA and 
average peak of 
accelerations 
measured with 
Actilog activity 
monitor did not 
show statistical 
significant 
differences at 
various time 
points 
months 92+/-
7.3, 18 
months 98+/-
7.8, and 24 
months was 
93+/- 8.2. 
 Average 
peaks: 3 
months 121+/-
4.9, 6 months 
125+/-5.0, 12 
months 127+/-
5.4, 18 
months 126+/-
5.7, and 24 
99 
 
months 127+/-
6.1. 
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Abbreviations: 
LSS – Limb Sparing Surgery 
AMP – Amputation 
vs  - Versus 
BT – Bone tumour 
TKR – Total knee replacement 
THR – Total hip replacement 
TESS – Toronto Extremity Salvage Score 
MSTS - Musculoskeletal Tumour Society Rating Scale 
Rand 36 – Rand 36-Item Health Survey 
QOL – Quality of life 
ACP - Displacement of amplitude of the centre of pressure 
VCP - Velocity of the centre of pressure 
PA – Physical Activity 
GC – Gait cycle 
gcs – Gait cycles 
101 
 
GPA – General physical activity 
ASKp-38 - Activity scale for kids 
SAM - Step activity monitor 
m/s2 = Movement intensity 
mm/sec = millimetre per second 
m/s = metre per second 
cm/s – centimetre per second 
m/min – metre per minute 
km/hr – kilometre per hour 
s  = second 
m = metre 
/day – per day 
ICC - Intraclass correlation coefficient 
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Table 4: Quality Assessment of Articles 
 
Section 1: Criteria for assessing quality of studies.        
 
 
A. The study mentions a clear scientific background and rationale for conducting the 
investigation.  
B. The study mentions clear aim/objectives and/or including hypothesis. 
C. Use of an appropriate study design to address the aim/objectives - Prospective study 
design (also positive in studies where previously unknown outcomes are measured in 
a historical cohort, case series or cross-sectional patient group) 
D. The study size calculation is explained – to ensure appropriately powered. 
E. Study population was well defined and types of sarcoma described. 
F. Socio-demographic data mentioned. 
G. Time since diagnosis reported. 
H. Participant eligibility criteria outlined and the methods and sources of 
selection/recruitment. 
I. Data collection process has been described. 
J. Type of sarcoma interventions has been reported. 
K. Presence of a control group for relevant studies (no score if study data was compared 
to literature) 
L. Participation rate (score given if rate of participation > 75%). 
M. Use of a standardised and valid assessment tool (internal validity)  
N. Precision of result reported. 
O. Mention of efforts to reduce any potential sources of bias (example: selection bias, 
performance bias). 
P. The impact of confounding factors on outcome was clearly mentioned (example: age, 
time since surgery, level of surgery, rehabilitation interventions etc). 
Q. Use of an appropriate statistical analysis tests to answer meet the aim/objectives.  
R. Generalisability (external validity) of the results to a local population (for example: 
results when patients are receiving treatments in hospitals or outpatient 
departments). 
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Adapted from following sources: 
 
(Kwong, Furtado et al. 2014), CASP [Critical Appraisal Skills Programme (CASP) 2014], STROBE (Elm, 
Altman et al. 2007). 
 
References: 
 
CASP [Critical Appraisal Skills Programme (CASP) 2014], CASP Checklists [URL used], Oxford. CASP 
 
Elm, E. v., et al. (2007). "Strengthening the reporting of observational studies in epidemiology 
(STROBE) statement: guidelines for reporting observational studies." BMJ 335(7624): 806-808. 
 
Kwong, T. N., et al. (2014). "What do we know about survivorship after treatment for extremity 
sarcoma? A systematic review." Eur J Surg Oncol 40(9): 1109-1124. 
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Section 2: Quality Scoring of Articles. 
S.
No 
Article A B C D E F G H I J K L M N O P Q R Scor
e 
(%) 
 
Quality 
Rating  
1.  De 
Visser et 
al, 2001 
+ + + - + + - - + + + - + + - - + - 11(61
) 
Moderate 
2.  De 
Visser et 
al, 1998 
+ + + - + +      + - + + + - + + - - + - 12(67
) 
Moderate 
3.  De 
Visser et 
al, 2000 
+ + + - + + + - + + + - + + - - + - 12(67
) 
Moderate 
4.  Kawai et 
al, 2000 
- + - - + + + - + + + - + + - - + - 10(56
) 
Moderate 
 
5.  De 
Visser et 
al, 2003 
+ + + - + + + - + + - - + + - - + - 11(61
) 
Moderate 
6.  Tsauo et 
al, 2006 
+ + + - + + + + + + + + 
(80% 
partici
pation 
rate as 
20 out 
of 25 
partici
pated) 
+ + - - + + 15(83
) 
High 
7.  Beebe et 
al, 2009 
+ + - - + + + + + + n
/
a 
- + + - - + - 11(65
) 
 
Moderate 
8.  Zohman 
et al, 
1997 
+ + + - + + + - + + + -  
(34% 
as 10 
out of 
29 
patient
s 
partici
pated) 
+ + - - + - 12(67
) 
Moderate 
9.  Rosenba
um et al, 
2008 
+ + + - + + + + + + + - + + - - + + 14(78
) 
High 
10.  Sheiko et 
al, 2012 
+ + + - + + + + + + + - + + - - + + 14(78
) 
High 
11.  Van deer 
Geest et 
al, 2012 
+ + + - + + + + + + +  - + + - - + + 14(78
) 
High 
12.  Winter et 
al, 2012 
+ + + - + + + + + + + + 
(80% 
partici
pation 
rate as 
20 out 
of 25 
partici
pated) 
+ + - - + + 15(83
) 
High 
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13.  Sugiura 
et al, 
2001 
+ + + - + + + - + + + - + + - - + + 13(72
) 
High 
 
 
 
S.
No 
Article A B C D E F G H I J K L M N O P Q R Scor
e 
(%) 
 
Quality 
Rating  
14.  Van Dam 
et al, 2001 
+ + + - + + + + + + - - + + - - + + 13(72) High 
 
15.  Hopyan 
et al, 
2006 
+ + + - + + + + + + - - (37% 
as 45 
out of 
123 
patient
s 
partici
pated) 
+ + - -  + + 13(72
) 
 
 
 
 
High 
16.  Winter et 
al, 2009 
+ + + - + + + + + + + - (65% 
as 80 
out of 
123 
patient
s 
partici
pated) 
+ + - - + + 14(78
) 
High 
17.  Bekkerin
g et al, 
2011 
+ + + - + + + + + + - + 
(75% 
as 82 
out of 
110 
partici
pated) 
+ + - + + + 15(83
) 
High 
18.  Bekkerin
g et al, 
2012 
+ + + - + + + + + + - - (90% 
44 out 
of 49 
recruit
ed,  
partici
pated 
in 
initial 
asses
sment) 
and 
49% , 
24 out 
of 49 
compl
eted 
the 
study 
at 2 
years) 
+ + - + + + 14(78
) 
High 
 
 
